Poor Sleep
Sanofi India Limited and Cipla Limited have announced an exclusive partnership for distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India. As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium®, a leading brand in the anti-epileptic medication category.
While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla will leverage its capabilities and robust India-wide network of strong marketing and sales professionals, distributors, institutions, and market outreach programs to expand access to these treatments for patients who need them.
Recognizing the increasing burden of non-communicable diseases (NCDs) and the pivotal role of improving understanding…
The BJP-led Delhi government on Saturday entered into an agreement with the Union health ministry…
In a one of its kind research, India is set to begin an inter-ministerial scientific…
As an ode to Dr. Samuel Hahnemann, the founder of homoeopathy, on his birth-anniversary on…
RJD president and former Bihar chief minister Lalu Prasad was on Wednesday taken to Delhi…
The Indian Society for Extracellular Vesicles (InSEV) successfully hosted its inaugural conference, EVOLVE 2025, from…